StreetAlpha.app
Home › Stocks › PMCB

PharmaCyte Biotech, Inc. (PMCB)

$3.98
▼ −12.83%
LAST CLOSE · NOV 20

PharmaCyte Biotech develops cancer cell therapies using its Cell-in-a-Box encapsulation technology, based in Las Vegas. It last closed at $3.98 on Nov 20, down 12.83% on the day. For the quarter ended Jul 2026, PMCB reported EPS of -$0.54 on revenue of $0. Over the last 12 months PMCB insiders bought $129K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is PMCB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PMCB.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$16.1M
EPS (diluted)
−$2.08
−3566.7% vs a year ago
Valuation
Market cap
$42.7M
10.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$17.7M
At Jul 31
Shareholder equity
$27.5M
Shares outstanding
10.7M
At Sep 11
Fiscal year endsApril
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025FY2026: $0$0FY2026

From PMCB's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 14). Last 12 months adds up the four latest quarters.

Last report
Jul 11
2022 · next date not set yet
Reported EPS
-$0.54
Quarter ended Jul 2026
Year ago EPS
-$1.23
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Oct 2024: -$0.39Oct '24Jan 2025: -$0.44Jan '25Apr 2025: $1.52Apr '25Jul 2025: -$1.23Jul '25Oct 2025: -$1.24Oct '25Jan 2026: -$0.17Jan '26Apr 2026: -$0.36Apr '26Jul 2026: -$0.54Jul '26Latest -$0.54
Revenue by quarter
Oct 2024: $0Oct '24Jan 2025: $0Jan '25Apr 2025: $0Apr '25Jul 2025: $0Jul '25Oct 2025: $0Oct '25Jan 2026: $0Jan '26Apr 2026: $0Apr '26Jul 2026: $0Jul '26Latest $0
How PMCB moved after its last 1 report
Average move the session after a report ±1.7%
Jul 11, 2022After the close+1.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PMCBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Technical Analysis

PMCB · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 60% below its 20 day and 78% below its 50 day average. It is 189% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot S1 at $3.79, and the nearest resistance the 52 week low at $3.98.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 23.1%/day
Key levels
$28.6952 week high+620.9%
$11.50200 day average+188.9%
$9.02100 day average+126.6%
$7.60Swing high (Oct 23)+91.0%
$7.0650 day average+77.4%
$6.3720 day average+60.1%
$4.35Pivot R1+9.3%
$4.16Pivot+4.5%
$3.9852 week low+0.0%
$3.98Last close
$3.79Pivot S1−4.8%
Indicators
RSI (14)25.10Oversold below 30Oversold
MACD-0.60Below its signal lineBearish
Stochastic6.4Near the bottom of its rangeOversold
ADX (14)26.1Trending down
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-204.9Oversold below −100, overbought above 100Oversold
Rate of change−41.9%Change over 10 sessionsBearish
ATR (14)$0.92Typical daily range, 23.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PMCB

What happened before

See how PMCB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PMCB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PMCB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PMCBHow many large options trades hit PMCB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PMCB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 18 selling
  • ▼Held by funds -0.8 pts
  • ▼Funds holding -6
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2733−18.2%
In funds' top 1000–
Held by funds6.3%7.1%−0.8 pts
New / increased4 / 24 / 6−40.0%
Reduced / sold out9 / 99 / 6+20.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PMCB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PMCB Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$129K2 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $129K between Jan 5 and Jan 7.
2026-01 bought $129KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jan 7Jonathan SchechterDirectorBuy60,000$0.80$48K
Jan 7Joshua SilvermanCEO and PresidentBuy100,000$0.80$80K
Every insider buy and sale for PMCB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PMCB insider trades →

From SEC Form 4 filings by PMCB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMCB is in one of them and how their past PMCB trades turned out.

PMCB in the AI portfolios
Loading…

PMCB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PMCB in an article yet. Here's the latest on the wider market.

PMCB in the news

About PharmaCyte Biotech

PharmaCyte Biotech is a biotechnology company based in Las Vegas, Nevada, that develops cell therapies for cancer. Its Cell-in-a-Box technology places genetically engineered live human cells inside small capsules made mostly of cellulose, which are positioned near a tumor. Its main product candidate, CypCaps, is being developed for patients with locally advanced pancreatic cancer. Spending on these development programs has been reduced while the company reviews them.

Headquarters
Las Vegas, NV